Update: The coming into force date of the amended Patented Medicines Regulations has been deferred, once again, until July 1, 2022, which as announced on April 14, 2022, will be released in a substantially amended form.
Further to our last update on the amendments to the Patented Medicines Regulations (see
here) and related Guidance (see
here), the Patented Medicine Prices Review Board (PMPRB) has today
announced
that:
- The coming into force date of the amended Patented Medicines Regulations will now be January 1, 2021; and
- A revised set of draft Guidelines will be published the week of June 15, 2020 followed by a 30-day consultation period.
The most immediate and practical impact of this change is that reporting requirements due by July 30, 2020 of sales and pricing information for the period from January 1, 2020 to June 30, 2020 will clearly be governed by the current Regulations (see our later article here).
Related Publications & Articles
-
Update on biosimilars in Canada – March 2023
In this article, we provide a further update on developments regarding biosimilars in Canada.Read More -
CADTH consultation on time-limited reimbursement initiative, and IMC report on what Canada can learn from Europe
The Canadian Agency for Drugs and Technologies in Health has released a consultation document for a Proposed Process for Time-limited Reimbursement Recommendations.Read More -
House of Commons Standing Committee on Health meets for study of the PMPRB
The Standing Committee on Health (HESA) of the House of Commons met on Thursday, April 27, 2023, to begin its study of the Patented Medicine Prices Review Board (PMPRB).Read More